Viking Therapeutics Inc. (VKTX)
Summary
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
Viking Therapeutics Q2 Earnings Call Highlights
Viking Therapeutics NASDAQ: VKTX reported a wider second-quarter loss as the company increased spending to advance its obesity pipeline, including its lead dual GLP-1/GIP receptor agonist, VK2735, through Phase III development in injectable and planned oral formulations.
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?
Biotech earnings take center stage as Viking, Biogen, Bristol Myers, Regeneron and AbbVie prepare to report Q2 2026 results.
Viking Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 400 | $17,492 | $12,696 | -$4,796 | -27.42% |
 Curtis Ellergodt Rothschild Investment LLC | 8 | $262.5 | $266.4 | $3.9 | 1.49% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 49,464 | $1.93M | $1.69M | -$234,950.36 | -12.18% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 16,451 | $426,491.46 | $559,663.02 | $133,171.56 | 31.22% |
| MA mason adams PVG ASSET MANAGEMENT Corp. | 19,818 | $556,683.37 | $629,023.32 | $72,339.95 | 12.99% |
Viking Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HP Hardik Parikh JP Morgan | 598.99 | $20,245.98 | $20,377.76 | $131.78 | 0.65% |
| DB Daniel Brims Lake Street | 1,519.33 | $50,154.55 | $51,444.55 | $1,290 | 2.57% |
Viking Therapeutics Inc. (VKTX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Viking Therapeutics Inc. ever had a stock split?
Viking Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Lian CEO | NASDAQ (CM) Exchange | 92686J106 CUSIP |
| US Country | 65 Employees | - Last Dividend | - Last Split | 29 Apr 2015 IPO Date |
Overview
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for metabolic and endocrine disorders. Established in 2012 and based in San Diego, California, Viking Therapeutics embarks on fulfilling the unmet needs within this domain by advancing a diverse portfolio of novel therapeutic candidates. Their approach leverages deep insight into disease mechanisms, aiming at delivering significant improvements over existing therapies.
Products and Services
-
VK2809:
An orally available, selective agonist of the thyroid hormone receptor beta (TRβ), primarily focused on treating non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Currently in Phase IIb clinical trials, VK2809 demonstrates Viking Therapeutics' commitment to addressing serious liver conditions through innovative therapeutic mechanisms.
-
VK5211:
A novel, orally available non-steroidal selective androgen receptor modulator (SARM) aimed at improving recovery in patients undergoing non-elective hip fracture surgery. Presently in Phase II clinical trials, VK5211 is designed to provide anabolic improvements of both muscle and bone, potentially representing a significant advance in post-operative care for this patient population.
-
VK0612:
Targeting the treatment of type 2 diabetes, VK0612 is an oral drug candidate ready for Phase IIb trials. By focusing on a crucial aspect of metabolic disease management, VK0612 underscores Viking's broader strategy in addressing complex metabolic disorders via cutting-edge pharmacological solutions.
-
VK2735:
This novel compound acts as a dual agonist of the glucagon-like peptide, currently in a Phase 1 single ascending dose/multiple ascending dose (SAD/MAD) clinical trial. VK2735's development signifies Viking Therapeutics' foray into innovative treatments that could potentially offer new options for managing metabolic diseases through unique mechanisms of action.
-
VK0214:
An orally available, selective agonist of the TRß tailored for addressing symptoms and progression of X-linked adrenoleukodystrophy. Through its clinical development, VK0214 epitomizes Viking's dedication to exploring therapeutic avenues for rare and underserved endocrine disorders, providing hope for patients and families affected by these challenging conditions.
